A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients

NCT02096601 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson's Disease

Interventions

DRUG: LD/CD SC solution
DRUG: Entacapone

Sponsor

NeuroDerm Ltd.

Collaborators

[object Object]